This product combines two of the most-studied recovery-research peptides, BPC-157 and TB-500 (Thymosin Beta-4), in a single lyophilized vial. BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV; C62H98N16O22; ~1419.5 g/mol; CAS 137525-51-0; PubChem CID 9941957) derived from a gastric-juice protein and studied for angiogenic and nitric-oxide-mediated tissue-repair mechanisms. TB-500 corresponds to full-length Thymosin Beta-4, a 43-residue N-acetylated peptide (C212H350N56O78S; ~4963 g/mol; CAS 77591-33-4; PubChem CID 16132341) that acts primarily by sequestering monomeric G-actin.
The two peptides are frequently paired in preclinical connective-tissue research because their proposed mechanisms are complementary: BPC-157 emphasizes vascular and nitric-oxide pathways, while TB-500 emphasizes actin-driven cell migration and cytoskeletal remodeling. Helio offers this blend in 5mg+5mg and 10mg+10mg vial configurations. This material is Research Use Only and is not for human or veterinary use.
BPC-157: GEPPPGKPADDAGLV (15 aa); TB-500: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 aa)
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
The BPC-157 / TB-500 pairing is a common preclinical combination in recovery research because the two peptides target distinct but complementary processes, vascular and nitric-oxide signaling for BPC-157 and actin-cytoskeleton regulation and cell migration for TB-500. Individual-compound studies (Sikiric et al. for BPC-157; Malinda et al. and Goldstein et al. for Thymosin Beta-4) document angiogenic and tissue-repair endpoints in rodent and in-vitro models.
No controlled study establishes synergy or human efficacy of the blend itself; the two peptides are simply co-formulated for research convenience. All associated data are experimental and hypothesis-generating.
BPC-157 (from gastric-juice Body Protection Compound, 1990s) and Thymosin Beta-4 (isolated from thymus, characterized since the 1980s) each have independent experimental histories; their combination as a research blend reflects their shared use in connective-tissue and wound-repair studies. Both remain unapproved investigational compounds for laboratory research only.
Cited literature refers to laboratory and preclinical research. BPC-157 + TB-500 Blend is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
